Three Calif. teens arrested for assault after girl's suicide

SAN JOSE, Calif. (AP) ? Eight days after allegedly being sexually battered while passed out at a party, and then humiliated by online photos of the assault, 15-year-old Audrie Pott posted on Facebook that her life was ruined, "worst day ever," and hanged herself.

For the next eight months, her family struggled to figure out what happened to their soccer loving, artistic, horse crazy daughter, whose gentle smile, long dark hair and shining eyes did not bely a struggling soul.

And then on Thursday, seven months after the tragedy, a Northern California sheriff's office arrested three 16-year-old boys on charges of sexual battery.

"The family has been trying to understand why their loving daughter would have taken her life at such a young age and to make sure that those responsible would be held accountable," said family attorney Robert Allard.

"After an extensive investigation that we have conducted on behalf of the family, there is no doubt in our minds that the victim, then only 15 years old, was savagely assaulted by her fellow high school students while she lay on a bed completely unconscious."

Allard said students used cell phones to share photos of the attack, and that the images went viral.

Santa Clara County Sheriff's Lt. Jose Cardoza said it arrested two of the teens at Saratoga High School and the third, a former Saratoga High student, at Christopher High School in Gilroy on Thursday. The names of the suspects were not released because they are minors.

Cardoza said the suspects were booked into juvenile hall and face two felonies and one misdemeanor each, all related to sexual battery that allegedly occurred at a Saratoga house party.

The lieutenant said the arrests were the result of information gathered by his agency's Saratoga High School resource officers. He said the investigation is ongoing, and Los Gatos police also continue looking into the girl's September suicide.

The Associated Press does not, as a rule, identify victims of sexual assault. But in this case, Pott's family wanted her name and case known, Allard said. The family also provided a photo to the AP.

The girl's family members did not comment and have requested privacy until a planned news conference Tuesday. Her father and step-mother Lawrence and Lisa Pott, along with her mother Sheila Pott, have started the Audrie Pott Foundation (audriepottfoundation.com) to provide music and art scholarships and offer youth counseling and support.

The foundation website alludes to the teen's struggles, but until now neither law enforcement, school officials nor family have discussed the sexual battery.

"She was compassionate about life, her friends, her family, and would never do anything to harm anyone," the site says. "She was in the process of developing the ability to cope with the cruelty of this world but had not quite figured it all out.

"Ultimately, she had not yet acquired the antibiotics to deal with the challenges present for teens in today's society."

On the day Pott died, Saratoga High School principal Paul Robinson announced her death, stunning classmates. Two days later other students and staff wore her favorite color, teal, in her honor.

Robinson wasn't immediately available for comment Thursday.

The Pott family is not alone.

In Canada on Thursday, authorities said they are looking further into the case of a teenage girl who hanged herself Sunday after an alleged rape and months of bullying. A photo said to be of the 2011 assault on 17-year-old Rehtaeh Parsons was shared online.

No charges initially were filed against four teenage boys being investigated. But after an outcry, Nova Scotia's justice minister appointed four government departments to look into Parsons' case.

Source: http://news.yahoo.com/3-teens-arrested-assault-girls-suicide-024221519.html

grenada Sikh Sanya Richards Ross decathlon Honey Boo Boo Child marilyn monroe Nathan Adrian

Libya releases four Egyptian Christians: MENA

CAIRO (Reuters) - Libya on Thursday released four Egyptian Christians who spent more than a month in jail after being accused of proselytizing, Egypt's state news agency MENA said.

Quoting church sources, MENA said Libyan authorities had dropped the charges against them. A fifth detained Egyptian died in a Tripoli prison last month, it added.

The release comes after Egypt extradited two members of the regime of ousted Libyan leader Muammar Gaddafi earlier this month. An Egyptian court barred the extradition of a cousin of Gaddafi claiming to hold Egyptian citizenship.

Last month, Egyptian judicial sources told Reuters Egypt was seeking to swap the Libyans with the Egyptian Copts.

On Wednesday, Libya decided to grant Egypt, struggling with economic and political turmoil, a $2 billion five-year interest-free loan.

Libya's small Christian community has expressed fears over Islamist extremism as the government struggles to impose its authority over armed groups which have refused to lay down their weapons since the 2011 war that ousted Gaddafi.

In December, an explosion at a building belonging to a Coptic church in Dafniya, close to the western Libyan city of Misrata, killed two Egyptian men and wounded two others.

Source: http://news.yahoo.com/libya-releases-four-egyptian-christians-mena-090624493.html

nick collins dave matthews ambien wwdc madden 13 cover dalai lama tamera mowry

Michigan, solid all around, scorches Syracuse

The Michigan Wolverines advanced to the NCAA national championship game Saturday night, beating the Syracuse Orange 61-56. Michigan will face the Louisville Cardinals Monday night at 9:23 p.m.

By Paul Newberry,?AP National Writer / April 7, 2013

Michigan's Caris LeVert (23) passes the ball as Syracuse's C.J. Fair (5) looks on during the second half of the NCAA Final Four tournament college basketball semifinal game Saturday, April 6, 2013, in Atlanta. Michigan won the game 61-56.

David J. Phillip/AP

Enlarge

Michigan is more than just five fabulous players.

Skip to next paragraph

' + google_ads[0].line2 + '
' + google_ads[0].line3 + '

'; } else if (google_ads.length > 1) { ad_unit += ''; } } document.getElementById("ad_unit").innerHTML += ad_unit; google_adnum += google_ads.length; return; } var google_adnum = 0; google_ad_client = "pub-6743622525202572"; google_ad_output = 'js'; google_max_num_ads = '1'; google_feedback = "on"; google_ad_type = "text"; google_adtest = "on"; google_image_size = '230x105'; google_skip = '0'; // -->

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of
The Christian Science Monitor
Weekly Digital Edition

No, this is quite a team ? all the way down the roster.

Fearlessly attacking Syracuse's suffocating zone in the first half, getting big contributions off the bench, and hanging on for dear life at the end, the Wolverines advanced to the national championship game with a 61-56 victory over the Orange in the?Final?Four?on Saturday night.

So put away those comparisons to the Fab Five.

This group of young stars is determined to leave its own legacy.

"We've been a team all year," said coach John Beilein, whose Wolverines were playing in the?Final?Four?for the first time since 1993, when the Fab Five lost for the second straight time in the national title game. "It was great."

Michigan (31-7) will be going for its first national title since 1989 when it faces Louisville on Monday at the Georgia Dome. Syracuse (30-10) failed to complete an all-Big East?final?in the fabled league's last season before a major overhaul.

Louisville was established as a 4 1/2-point title game favorite.

Don't expect that to bother the brash young Wolverines a bit. They showed they could win even when their best weapon, Associated Press player of the year Trey Burke, was having a really ugly night.

He scored just seven points on 1-of-8 shooting.

"We know Trey is our leader, and sometimes he's not going to have a game like he's had all season," said Tim Hardaway Jr., who led Michigan with 13 points. "That's when our team stepped up."

Trailing 58-56, the Orange had a chance to force overtime. But Brandon Triche was called for a foul when Jordan Morgan stepped in to take the charge with 19.2 seconds left.

"Jordan is our best charge-taker," Beilein said. "He stood in there and took a good one."

After Jon Horford made only one of two free throws, Syracuse called timeout and set up a play. Curiously, the Orange didn't attempt a tying 3-pointer. Instead, Trevor Cooney drove the lane looking to put up an easier shot. But the ball was swatted away, Michigan saved it from going out of bounds and Morgan wound up taking a long pass the other way.

He threw down a thunderous slam with just over a second remaining to cap the triumph.

Triche blamed himself for driving the ball recklessly into the lane when Syracuse had a chance to tie it.

Source: http://rss.csmonitor.com/~r/feeds/csm/~3/3iJxz8Z37CU/Michigan-solid-all-around-scorches-Syracuse

kevin youkilis Tropical Storm Debby legend of korra magic mike trailer Alan Turing brave Stephanie Rice

Bravo Gives Kathy Griffin?s Talk Show The Axe!

Bravo Gives Kathy Griffin’s Talk Show The Axe!

Ginger funnywoman Kathy Griffin has confirmed that her talk show on Bravo has been cancelled. Griffin announced that she would not be returning for a third season on the show during a stand-up gig in Cincinnati, Ohio on Friday. Kathy told the audience that she?d been informed by Bravo of the decision the previous day. ...

Bravo Gives Kathy Griffin’s Talk Show The Axe! Stupid Celebrities Gossip Stupid Celebrities Gossip News

Source: http://stupidcelebrities.net/2013/04/bravo-gives-kathy-griffins-talk-show-the-axe/

solar storm solar flares spanx aurora borealis gcb mary j blige dionne warwick

Arrhythmia drug may increase cancer risk - Cancer -Drug Abuse -

? Cancer ? ? Drug Abuse ? Apr 07, 2013

One of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug. That is the conclusion of a new retrospective study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study?s results indicate that a potential link between amiodarone and cancer warrants further investigation.

Amiodarone was approved in 1985 for the treatment of arrhythmias, or irregular heartbeats. Because the drug is fat-soluble and degrades very slowly, large amounts can accumulate in soft tissues after a long-term prescription. Previous studies have shown that amiodarone might increase the risk of certain cancers, but no large-scale study has looked at the issue.

To investigate, Vincent Yi-Fong Su, MD, of the Taipei Veterans General Hospital in Taiwan, and his colleagues studied 6,418 individuals taking the drug, following them for an average of 2.57 years. A total of 280 participants developed cancer.

Patients who were male or who received high cumulative daily doses of amiodarone within the first year had an increased risk of developing cancer. Those with both factors were 46 percent more likely to develop cancer than those with neither factor. After taking age, sex, and illnesses into account, individuals taking a high amount of amiodarone had nearly twice the risk of developing cancer as those taking a low amount of the drug.

"We suggest that cancer events should be routinely reported in future amiodarone trials, and further observational research is necessary,? said Dr. Su. ?Also, when prescribing amiodarone, doctors need to keep in mind that this medication may increase cancer risk.?

###

Amy Molnar
sciencenewsroom@wiley.com
Wiley

Provided by ArmMed Media

?Comments

[ + Post Your Own ]?

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]

Source: http://www.health.am/ab/more/arrhythmia-drug-may-increase/

little league world series us open tennis us open tennis Empire State Building shooting Republican National Convention Karlie Redd guild wars 2

First trial to investigate magic mushrooms as a treatment for depression delayed by UK and EU regulations

Apr. 5, 2013 ? The world's first clinical trial to explore the use of the hallucinogenic ingredient in magic mushrooms to treat depression is being delayed due to the UK and EU rules on the use of illegal drugs in research.

Professor David Nutt, president of the British Neuroscience Association and Professor of Neuropsychopharmacology at Imperial College London (UK), will tell the BNA's Festival of Neuroscience today (Sunday) that although the UK's Medical Research Council has awarded a grant for the trial, the Government's regulations controlling the licensing of illegal drugs in research and the EU's guidelines on Good Manufacturing Practice (GMP) have stalled the start of the trial, which was expected to start this year. He is calling for a change to the regulations.

He will tell the meeting at the Barbican in London, that his research has shown that psilocybin, the psychedelic ingredient in magic mushrooms, has the potential to alleviate severe forms of depression in people who have failed to respond fully to other anti-depressant treatments. However, psilocybin is illegal in the UK; the United Nations 1971 Convention on Psychotropic Substances classifies it as a Schedule 1 drug, one that has a high potential for abuse with no recognised medical use, and the UK has classified it as a Class A drug, the classification used for the most dangerous drugs. This means that a special licence has to be obtained to use magic mushrooms in research in the UK, and the manufacture of a synthetic form of psilocybin for use in patients is tightly controlled by EU regulations.

Prof Nutt will say: "The law for the control of drugs like psilocybin as a Schedule 1 Class A drug makes it almost impossible to use them for research and the reason we haven't started the study is because finding companies who could manufacture the drug and who are prepared to go through the regulatory hoops to get the licence, which can take up to a year and triple the price, is proving very difficult. The whole situation is bedevilled by this primitive, old-fashioned attitude that Schedule 1 drugs could never have therapeutic potential, and so they have to be made impossible to access."

"The knock-on effect is this profound impairment of research. We are the first people ever to have done a psilocybin study in the UK, but we are still hunting for a company that can manufacture the drug to GMP standards for the clinical trial, even though we've been trying for a year to find one. We live in a world of insanity in terms of regulating drugs at present. The whole field is so bogged down by these intransient regulations, so that even if you have a good idea, you may never get it into the clinic."

He will say that the regulations need to be changed. "Even if I do this study and I show it's a really useful treatment for some people with depression, there's only four hospitals in this country that have a licence to hold this drug, so you couldn't roll out the treatment if it worked because the regulations would make it difficult to use," he said.

Prof Nutt and his team at Imperial College London (UK) have shown that when healthy volunteers are injected with psilocybin, the drug switched off a front part of the brain called the anterior cingulate cortex, which is known from previous imaging studies to be over-active in depression. "We found that, even in normal people, the more that part of the brain was switched off under the influence of the drug, the better they felt two weeks later. So there was a relationship between that transient switching off of the brain circuit and their subsequent mood," he will explain. "This is the basis on which we want to run the trial, because this is what you want to do in depression: you want to switch off that over-active part of the brain.

"The other thing we discovered is that the major site of action of the magic mushrooms is to turn down a circuit in the brain called the 'default mode network', which the anterior cingulate cortex is part of. The default mode network is a part of the brain between the front and back. It is active when you are thinking about you; it coordinates the thinking and emotional aspects of you."

The researchers discovered that the 'default mode network' had the highest density of 5HT2A receptors in the brain. These are known to be involved in depression and are the targets for a number of existing anti-depressive drugs that aim to improve levels of serotonin -- the neurotransmitter [1] that gives people a sense of well-being and happiness. Psilocybin also acts on these receptors.

"We have found that people with depression have over-active default mode networks, and they are continually locked into a mode of thinking about themselves. So they ruminate on themselves, on their incompetencies, on their badness, that they're worthless, that they've failed; these things are not true, and sometimes they reach delusional levels. This negative rumination may be due to a lack of serotonin and what psilocybin is doing is going in and rapidly replacing the missing serotonin, switching them back into a mind state where they are less ruminating and less depressed," Prof Nutt will say.

The proposed trial will be for patients with depression who have failed two previous treatments for the condition. Thirty patients will be given a synthetic form of psilocybin and 30 patients will be given a placebo. The drug (or placebo) will be given during two, possibly three, carefully controlled and prepared 30-60 minute sessions. The first session will be a low dose to check there are no adverse responses, the second session will give a higher, therapeutic dose, and then patients can have a third, booster dose in a later session if it's considered necessary. While they are under the influence of the drug, the patients will have guided talking therapy to enable them to explore their negative thinking and issues that are troubling them. The doctors will follow up the patients for at least a year.

"What we are trying to do is to tap into the reservoir of under-researched 'illegal' drugs to see if we can find new and beneficial uses for them in people whose lives are often severely affected by illnesses such as depression. The current legislation is stopping the benefits of these drugs being explored and for the last 40 years we have missed really interesting opportunities to help patients."

Ethical approval for the trial was granted in March and Prof Nutt says he hopes to be able to start the trial within the next six months -- so long as he can find a manufacturer for the drug.

[1] Neurotransmitters are chemicals that transmit signals from neurons (nerve cells) to target cells.

[2] Funding: The Beckley Foundation has funded part of Prof Nutt's research, and the Medical Research Council has agreed a grant for the proposed clinical trial.

Abstract title: "Can we use psychedelic drugs to treat depressions?" Symposium: "Treating depression with antidepressants: where are we now and where are we going?"

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by British Neuroscience Association, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/mind_brain/depression/~3/pA07KX3YSxA/130407090832.htm

Royal Rumble 2013 senior bowl norovirus Coachella 2013 Eclampsia Kendrick Lamar JJ Abrams

Rumor: Microsoft Cloning Google Glass Too for 2014

Microsoft is supposedly building Smart Glasses too.

Last week brought reports that Chinese search giant Baidu is working on a clone of Google Glass. The news stemmed from an April Fools' joke that "spun out of control," but a rep from the company said there is a hint of truth behind the joke, that internal testing is in progress to produce something similar to Glass.

Now there is a rumor that Microsoft is doing the same, only the Redmond company is expected to produce a working product in 2014. The rumor stems from analyst Brian White, who informed investors of his theory about Microsoft's Internet-connected specs on Thursday.

Unfortunately, he didn't provide any extra specifics. But Microsoft's entry into the wearable tech realm really isn't all that far-fetched, and it wouldn't be surprising if the company actually introduces a prototype during BUILD 2013 or E3 2013 this June. A Windows 8-based set of specs that connect to a Windows-based tablet, smartphone and/or PC? You bet. Console connectivity is even likely.

"It appears to us that Google has made significant breakthroughs around software applications as it relates to this new product," he said. "As such, we believe this initiative will kick off a major push into the field of wearable electronics and therefore will be closely scrutinized."

Apple is reportedly taking a different avenue by developing the much-rumored iOS-powered iWatch. White also said that Apple is working on the iRing, which will interact with the upcoming iTV slated for a late 4Q13 release. This ring, acting as a navigation pointer, will help enhance motion detection and allow users to control the television set using hand gestures. The iWatch will supposedly interact with iTV as well.

Last month, Samsung confirmed that it, too, is working on a Smart Watch. "We?ve been preparing the watch product for so long," said Lee Young Hee, executive vice president of Samsung?s mobile business, in an interview with Bloomberg. "We are working very hard to get ready for it. We are preparing products for the future, and the watch is definitely one of them."

Marshal Cohen, an analyst at NPD Group, later said that the race is on to redesign the mobile phone into something that you wear. "We?re going to see formidable competition coming from many different directions -- from device makers, accessory makers, even fashion designers," he said.

As for Microsoft, the company will likely not arrive late in the game as it did in the tablet and smartphone sectors. Developing wearable tech should actually be a given seeing that its two major competitors are busily working on gadgets. We suspect that Kinect and the Xbox brand will somehow be involved.

_{Contact Us for News Tips, Corrections and Feedback}

Source: http://www.pheedcontent.com/click.phdo?i=13a2593eb7fea59da4a8e5bc4b5a9078

Jael Strauss Alison Pill gizmodo cnet britney spears sprint Sam Bacile